Revision: FDA Guidance for Remote Evaluations
In April 2021, the US Food and Drug Administration (FDA) published a Guidance for Industry on remote evaluations. Anyone hoping at the time that the FDA would carry out these remote evaluations with the same or comparable status to an on-site inspection was mistaken. Even the title "Remote Interactive Evaluations" avoided the word inspection or audit. So, now the successor has been published as a draft. But not much has changed.
The only notable addition is that organisations must give their prior written consent for the remote interactive evaluation to be carried out. Measures that will be taken if this consent is not given are not mentioned.
And this time, comments on the draft are possible. In April 2021, it was merely pointed out that the document would be implemented immediately, without public participation in the development of the final guidelines.
Related GMP News
24.07.2024FDA Warning Letter to a Manufacturer of an Athlete Muscle Maintenance Creme
24.07.2024FDA describes detailed CAPA Procedure in Warning Letter
17.07.2024Congressional Scrutiny on FDA's Foreign Inspection Program puts Pressure on Agency
19.06.2024More FDA Inspections again - also in the EU?
12.06.2024GMP Problems with critical Medicinal Products - what now?
15.05.2024Lack of Quality Oversight: EU Non-Compliance Report issued to Omeprazole Manufacturer